NCT00445965View on ClinicalTrials.gov

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Brain and Central Nervous System TumorsIntraocular MelanomaLung CancerMelanoma (Skin)Metastatic CancerNeuroblastomaOvarian CancerRetinoblastomaSarcomaSmall Intestine Cancer
Interventions
GENETIC

DNA analysis

OTHER

immunologic technique

OTHER

pharmacological study

RADIATION

iodine I 131 monoclonal antibody 3F8

RADIATION

131I-3F8

Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00445965 - Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | Biotech Hunter | Biotech Hunter